Cargando…
KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients
OBJECTIVE: To advance the understanding of KCNQ2 encephalopathy genotype–phenotype relationships and to begin to assess the potential of selective KCNQ channel openers as targeted treatments. METHODS: We retrospectively studied 23 patients with KCNQ2 encephalopathy, including 11 treated with ezogabi...
Autores principales: | Millichap, John J., Park, Kristen L., Tsuchida, Tammy, Ben-Zeev, Bruria, Carmant, Lionel, Flamini, Robert, Joshi, Nishtha, Levisohn, Paul M., Marsh, Eric, Nangia, Srishti, Narayanan, Vinodh, Ortiz-Gonzalez, Xilma R., Patterson, Marc C., Pearl, Phillip L., Porter, Brenda, Ramsey, Keri, McGinnis, Emily L., Taglialatela, Maurizio, Tracy, Molly, Tran, Baouyen, Venkatesan, Charu, Weckhuysen, Sarah, Cooper, Edward C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995058/ https://www.ncbi.nlm.nih.gov/pubmed/27602407 http://dx.doi.org/10.1212/NXG.0000000000000096 |
Ejemplares similares
-
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder
por: Tan, Aaron, et al.
Publicado: (2018) -
Ezogabine skin discoloration is reversible after discontinuation
por: Mathias, Sally V., et al.
Publicado: (2017) -
Two KCNQ2 Encephalopathy Variants in the Calmodulin-Binding Helix A Exhibit Dominant-Negative Effects and Altered PIP(2) Interaction
por: Tran, Baouyen, et al.
Publicado: (2020) -
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy
por: Ciliberto, Michael A, et al.
Publicado: (2012) -
Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
por: Weisenberg, Judith LZ, et al.
Publicado: (2011)